Curis lifesciences limited IPO Overview
Curis lifesciences limited IPO is a SME public issue offered through a Book Building issue with a total issue size of ₹27.52 Cr. The IPO price band is set at ₹120 to ₹128 per share, and retail investors can apply with a minimum investment of ₹2.56 L as per IPO guidelines.
The Curis lifesciences limited IPO opens on 7 Nov 2025 and closes on 11 Nov 2025. The IPO allotment is expected to be finalized on 12 Nov 2025, and the equity shares are proposed to be listed on NSE on 14 Nov 2025.
Investors can refer to the Curis lifesciences limited IPO RHP-DRHP for detailed information. The issue is managed by Finaax Capital Advisors Private Limited as the book running lead manager, while MUFG Intime India Private Limited (Link Intime) is the registrar to the IPO. Before investing, market participants often review IPO details, valuation, PE ratio, financials, and risk factors.
About curis lifesciences limited
The company manufactures pharmaceutical products globally and domestically on a loan license or contract basis, as well as for its own brand marketing.
The company serves over 100 corporate clients on loan licenses or contract manufacturing and 2 clients for its own brand marketing in Yemen and Kenya.
Products:
General pharmaceutical tablets and capsules
Oral liquids
External preparations
Sterile ophthalmic ointments
The company operates a state-of-the-art manufacturing facility in Sanand, Gujarat, adhering to stringent quality control measures to ensure product safety and efficacy.
As of July 31, 2025, the company has 95 permanent employees.
Competitive Strengths:
Experienced Promoters and Management Team
Wide range of Products
Strategic Location of Manufacturing Facility
Scalable Business Model
Quality assurance
Investment Objective
Capital Expenditure towards Construction of a Storage Facility
Pre-payment/Repayment of outstanding Secured Loans
Product Registrations in other countries
Funding our Working Capital Requirements
General Corporate Purposes